SEC Form 4 · accession 0001477932-16-009673
Citius Pharmaceuticals, Inc. · CTXR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard L Mazur
Director
Period of report
Mar 30, 2016
Accepted (ET)
Apr 12, 2016 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001506251
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 30, 2016 | P | 5,000,000 | $0.60 | A | 5,457,143 | D | |
| Common StockF1 | Mar 30, 2016 | J | 15,116,746 | $0.00 | A | 20,116,746 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common StockF2,F3 | $0.41 | Mar 30, 2016 | J | 0 | A | — | — | Common Stock | 0 | 3,594,217 | D |
| Warrant to Purchase Common StockF4 | $0.66 | Mar 30, 2016 | J | 0 | A | — | — | Common Stock | 0 | 3,668,978 | D |
| Warrant to Purchase Common StockF5 | $0.50 | Mar 30, 2016 | J | 0 | A | — | — | Common Stock | 0 | 4,197,149 | D |
| Warrant to Purcahse Common StockF6 | $0.66 | Mar 30, 2016 | J | 0 | A | — | — | Common Stock | 0 | 4,244,707 | D |
| Warrant to Purchase Common StockF7 | $0.50 | Mar 30, 2016 | J | 0 | A | — | — | Common Stock | 0 | 4,566,457 | D |
| Warrant to Purchase Common StockF8 | $0.50 | Mar 30, 2016 | J | 0 | A | — | — | Common Stock | 0 | 4,866,420 | D |
| Warrant to Purchase Common StockF9 | $0.50 | Mar 30, 2016 | J | 0 | A | — | — | Common Stock | 0 | 5,071,600 | D |
| Warrant to Purchase Common StockF10 | $0.50 | Mar 30, 2016 | J | 0 | A | — | — | Common Stock | 0 | 5,134,748 | D |
| Warrant to Purchase Common StockF11 | $0.41 | Mar 30, 2016 | J | 0 | A | — | — | Common Stock | 0 | 5,406,333 | D |
Explanation of responses
- F1Represents shares of the Issuer issued pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of March 30, 2016 by and among the Issuer, Citius LMB Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Issuer and Leonard-Meron Biosciences, Inc., a Delaware corporation ("LMB"). Pursuant to the terms of the Merger Agreement, each share of common stock of LMB and each convertible note of LMB was converted into shares of the Issuer's common stock.
- F10On March 14, 2016, the Reporting Person was granted a five-year warrant to purchase 34,877 shares of LMB common stock at an exercise price of $0.90 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 63,148 shares of the Issuer's common stock at a per share exercise of $0.50. The warrant is fully vested and exercisable immediately.
- F11On March 15, 2016, the Reporting Person was granted a five-year warrant to purchase 150,000 shares of LMB common stock at an exercise price $0.75 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 271,585 shares of the Issuer's common stock at a per share price of $0.41. The warrant is fully vested and exercisable immediately.
- F2On June 12, 2014, the Reporting Person was granted a five-year warrant to purchase 162,500 shares of LMB common stock at an exercise price of $0.75 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 294,217 shares of the Issuer's common stock at a per share exercise price of $0.41. The warrant is fully vested and exercisable immediately.
- F3Includes an option to purchase 3,300,000 shares of the Issuer's common stock at an exercise price of $0.45 per share granted to the Reporting Person on September 12, 2014 pursuant to the Issuer's 2014 Stock Incentive Plan. The option was previously reported on a Form 3 filed with the Commission on behalf of the Reporting Person on October 28, 2015 and amended on April 12, 2016.
- F4On January 8, 2015, the Reporting Person was granted a five-year warrant to purchase 41,292 shares of LMB common stock at an exercise price of $1.20 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 74,761 shares of the Issuer's common stock at a per share exercise price of $0.66. The warrant is fully vested and exercisable immediately.
- F5On August 18, 2015, the Reporting Person was granted a five-year warrant to purchase 291,717 shares of LMB common stock at an exercise price $0.90 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 528,171 shares of the Issuer's common stock at a per share exercise price of $0.50. The warrant is fully vested and exercisable immediately.
- F6On September 30, 2015, the Reporting Person was granted a five-year warrant to purchase 26,267 shares of LMB common stock at an exercise price of $1.20 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 47,558 shares of the Issuer's common stock at a per share exercise price of $0.66. The warrant is fully vested and exercisable immediately.
- F7On November 2, 2015, the Reporting Person was granted a five-year warrant to purchase 172,184 shares of LMB common stock at an exercise price of $0.90 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 311,750 shares of the Issuer's common stock at a per share exercise price of $0.50. The warrant is fully vested and exercisable immediately.
- F8On November 20, 2015, the Reporting Person was granted a five-year warrant to purchase 171,197 shares of LMB common stock at an exercise price of $0.90 per share. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 309,963 shares of the Issuer's common stock at a per share exercise price of $0.50. The warrant is fully vested and exercisable immediately.
- F9On January 8, 2016, the Reporting Person was granted a five-year warrant to purchase 113,324 shares of LMB common stock at an exercise price of $0.90. Pursuant to the Merger Agreement, the warrant was converted into a warrant to purchase 205,180 shares of the Issuer's common stock at a per share exercise price of $0.50. The warrant is fully vested and exercisable immediately.